Substituted benzamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same
Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
1. A compound, or a pharmaceutically acceptable salt thereof, having a structure represented by a formula:
wherein A is CR 2 or N;
wherein L is O or NR 7 ,
wherein R 1 is a five-membered or six-membered monocyclic heteroaromatic ring substituted with 0-3 of R 9 ;
wherein R 2 is hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, amino, hydroxyl, alkylamino, dialkylamino, NO 2 , CN, SO 2 R 8 , or COR 8 ;
wherein R 3 is selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, and CN;
wherein R 4 is selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C1-C6 haloalkoxy, hydroxyl, amino, alkylamino, dialkylamino, CN, SO 2 R 8 , and COR 8 , with the proviso that when A is N, then R 4 is selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, CN, SO 2 R 8 , and COR 8 ;
wherein R 5 is selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, CN, SO 2 R 8 , and COR 8 ;
wherein R 6 is selected from hydrogen, halogen, CN, C1-C6 alkyl, C3-C4 cycloalkyl, C3-C4 halocycloalkyl and C1-C6 haloalkyl;
wherein each of R 6a , R 6b , and R 6c is independently selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 haloalkoxy;
wherein R 7 is hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl;
wherein R 8 is C1-C6 alkyl, C1-C6 cycloalkyl, amino, alkylamino, or dialkylamino; and
wherein each R 9 , when present, is independently halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C4 cycloalkyl, C3-C4 halocycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxyl, amino, alkylamino, dialkylamino, NO 2 , CN, SO 2 R 8 , or COR 8 ;
wherein the compound exhibits partial or total inhibition of mGluR5 response to glutamate as a decrease in response to non-maximal concentrations of glutamate in human embryonic kidney cells transfected with rat mGluR5 in the presence of the compound, compared to the response to glutamate in the absence of the compound.
2. The compound of claim 1 , wherein A is CH.
3. The compound of claim 1 , wherein A is N.
4. The compound of claim 1 , wherein A is N and R 3 , R 4 , and R 5 are all H.
5. The compound of claim 1 , wherein L is O.
6. The compound of claim 1 , wherein R 1 is selected from pyridine and thiazole.
7. The compound of claim 1 , wherein R 1 is pyridine.
8. The compound of claim 1 , wherein R 2 is selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C1-C6 haloalkoxy.
9. The compound of claim 1 , wherein R 6 is selected from halogen, CN, C1-C6 alkyl, and C1-C6 haloalkyl.
10. The compound of claim 1 , wherein R 7 is hydrogen.
11. The compound of claim 1 , wherein R 8 is selected from C1-C6 alkyl, C1-C6 cycloalkyl, amino, alkylamino, and dialkylamino.
12. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 and a pharmaceutically acceptable carrier.
13. A compound, or a pharmaceutically acceptable salt thereof, having a structure represented by a formula:
wherein A is CR 2 or N;
wherein R 1 is a five-membered or six-membered monocyclic heteroaromatic ring substituted with 0-3 of R 9 ;
wherein R 2 is hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, amino, hydroxyl, alkylamino, dialkylamino, NO 2 , CN, SO 2 R 8 , or COR 8 ;
wherein R 6 is selected from hydrogen, halogen, CN, C1-C6 alkyl, C3-C4 cycloalkyl, C3-C4 halocycloalkyl and C1-C6 haloalkyl;
wherein R 8 is C1-C6 alkyl, C1-C6 cycloalkyl, amino, alkylamino, or dialkylamino; and
wherein each R 9 , when present, is independently halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C4 cycloalkyl, C3-C4 halocycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxyl, amino, alkylamino, dialkylamino, NO 2 , CN, SO 2 R 8 , or COR 8 .
14. The compound of claim 13 , wherein R 1 is selected from pyridine and thiazole.
15. The compound of claim 13 , wherein R 1 is pyridine.
16. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 13 and a pharmaceutically acceptable carrier.
17. A compound, or a pharmaceutically acceptable salt thereof, having a structure represented by a formula:
wherein A is CR 2 or N;
wherein R 1 is a five-membered or six-membered monocyclic heteroaromatic ring substituted with 0-3 of R 9 ;
wherein R 2 is hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, amino, hydroxyl, alkylamino, dialkylamino, NO 2 , CN, SO 2 R 8 , or COR 8 ;
wherein R 6 is selected from hydrogen, halogen, CN, C1-C6 alkyl, C3-C4 cycloalkyl, C3-C4 halocycloalkyl and C1-C6 haloalkyl;
wherein R 7 is hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl;
wherein R 8 is C1-C6 alkyl, C1-C6 cycloalkyl, amino, alkylamino, or dialkylamino; and
wherein each R 9 , when present, is independently halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C4 cycloalkyl, C3-C4 halocycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxyl, amino, alkylamino, dialkylamino, NO 2 , CN, SO 2 R 8 , or COR 8 .
18. The compound of claim 17 , wherein R 1 is selected from pyridine and thiazole.
19. The compound of claim 17 , wherein R 1 is pyridine.
20. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 17 and a pharmaceutically acceptable carrier.